High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients

BACKGROUND/AIMS: Patients with genotype 3 hepatitis C virus (G3-HCV) cirrhosis are very difficult to treat compared to patients with other HCV genotypes. The optimal treatment duration and drug regimen associated with ribavirin (RBV) remain unclear. To evaluate the efficacy and safety of daclatasvir...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Gut Liver
Huvudupphovsmän: Pellicelli, Adriano, Messina, Vincenzo, Giannelli, Valerio, Distefano, Marco, Palitti, Valeria Pace, Vignally, Pascal, Tarquini, Pierluigi, Izzi, Antonio, Moretti, Alessandra, Babudieri, Sergio, Dell’Isola, Serena, Marignani, Massimo, Scifo, Gaetano, Iovinella, Vincenzo, Cariti, Giuseppe, Pompili, Maurizio, Candilo, Francesco Di, Fontanella, Luca, Ettorre, Giuseppe M., Vennarecci, Giovanni, Ippolito, Antonio Massimo, Barbarini, Giorgio
Materialtyp: Artigo
Språk:Inglês
Publicerad: Editorial Office of Gut and Liver 2020
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7234881/
https://ncbi.nlm.nih.gov/pubmed/30970444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5009/gnl18269
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk